The goal of this observational study is to evaluate the clinical value of salivary 1,5-anhydroglucitol (1,5-AG) and assess a novel noninvasive detection approach in individuals with and without type 2 diabetes. Additionally, the study will examine the relationships of salivary 1,5-AG with serum 1,5-AG and continuous glucose monitoring (CGM) measures of short-term glycemic control and fluctuations.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Aged between 18 and 80 years.
2. Individuals without a history of diabetes, or patients with type 2 diabetes mellitus.
Exclusion Criteria:
1. History of systemic glucocorticoid treatment within the previous 6 weeks.
2. Presence of acute infection.
3. Presence of severe oral conditions that may affect saliva collection or measurement.
4. Presence of severe hepatic or renal dysfunction.
5. History of alcohol abuse or psychiatric disorders, including depression.
6. Current treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors.
Primary outcome measure(s)
Correlation Between Salivary 1,5-Anhydroglucitol and Glycemic Levels — Screening Salivary 1,5-anhydroglucitol (1,5-AG) will be measured by liquid chromatography-mass spectrometry or enzymatic assay. Glycemic levels will be assessed by fasting plasma glucose (mmol/L), glycated hemoglobin A1c (HbA1c, %), and glycated albumin (GA, %). Pearson or Spearman correlation coefficients will be used to assess their correlations with salivary 1,5-AG.
Trial sites (1)
Facility
City
Region
Status
Shanghai Sixth People's Hospital
Shanghai
Shanghai Municipality
More Shanghai 6th People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.